XIAP and hyperinsulinemic hypoglycemia, familial, 4: For XIAP deficiency patients, a phase 3 randomized clinical trial is ongoing (ClinicalTrials.gov Identifier NCT03113760) using rhIL-18BP, a protein that will regulate the elevated IL-18 cytokine levels that these patients manifest recurrently (131).